AI-powered search
Try Polaris, our new AI-powered search!

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Featuring James Del Rosso, DO | Clinical Advisor |

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

| Published April 28, 2022